Skip to content

Skin & hairAnti-aging & longevityHealing & recovery

GHK-Cu

Copper peptide · Copper tripeptide-1 · Gly-His-Lys copper

PreclinicalReviewed 12 Aug 2026

GHK is a three-amino-acid sequence, glycine-histidine-lysine, that occurs naturally in human plasma and binds copper with high affinity. The copper complex, GHK-Cu, has been studied since the 1970s, which makes it unusual in this category: there is a real, decades-long literature behind it.

The important qualifier is route. Most of that literature concerns topical application to skin, or laboratory work on cultured cells. It is used as a cosmetic ingredient in products sold legally worldwide. The injected use discussed in peptide communities is a different proposition, and the topical and cell-culture research does not transfer to it automatically.

It is also the component that gives GLOW and KLOW blends their characteristic blue colour, and typically the largest component by mass in those vials. Anyone dosing a blend by its BPC-157 content is taking considerably more GHK-Cu than they may realise.

How it works

GHK binds copper and appears to act as a carrier that delivers it to tissue. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, which is the most direct link between this peptide and the skin-remodelling effects reported for it.

Gene expression work in cultured cells has reported that GHK influences a large number of genes involved in tissue remodelling and inflammation. Those studies are in vitro; what a given dose does in a living person, by any route, is a separate question that the cell work does not answer.

Regulatory status — United States

Permitted as a topical cosmetic ingredient in the United States and widely sold as such. Not approved as an injectable medicine, and injectable material is a research chemical with no manufacturing standard behind it.

Last reviewed 12 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

Skin remodelling and appearance

Published review

The best-supported use, and the one the research base actually covers.

EvidenceHuman topical studies and cosmetic use. Applied to skin, not injected.

Wound healing

Published review

Studied for effects on dermal repair.

EvidenceAnimal and in vitro models, largely topical application.

Hair growth

Published review

Used in topical hair products.

EvidenceLimited human topical data.

Identity and clearance

Molecule

Class
Tripeptide-copper complex
Molecular weight
340.4 Da
Length
3 amino acids

Sequence

Gly-His-Lys (copper complex)

The copper ion is part of the active molecule, not an additive. This is also why solutions are blue.

Pharmacokinetics

Published review
Half-life1 h
Substantially cleared6 h
100%50%25%0%half-life 1hdose2h3h5h6h
Modelled from the half-life above, assuming first-order elimination. Illustrative rather than measured — it shows the shape of clearance, not a prediction for any individual.

Plasma GHK declines markedly with age. No pharmacokinetic study of injected GHK-Cu at community doses has been published.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
GoalDoseFrequencyRouteUnits, 50 mg vialSourceStart this protocol
Commonly described injected dose1 mg – 2 mgOnce dailySubcutaneous10–20 uCommunity practiceStart this
As delivered within a GLOW or KLOW blend1.25 mg – 2 mgOnce dailySubcutaneousIn a blend this is not chosen independently. It follows from the ratio in the vial and the dose you pick for whichever component you are dosing by.12.5–20 uCommunity practiceStart this

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Cycling

Community practice

4 to 6 weeks on, 2 to 4 weeks off.

A community convention. Copper accumulation is the usual stated reason for taking breaks, though no study establishes a threshold at these doses.

Calculator

Work out what to draw

Pre-filled with a 50 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Dose unit
Your syringe
010203040506070809010012.5 units0.125 mL

Draw to 12.5 units on a 1 mL U-100 syringe. That is 0.125 mL, containing 1.25 mg of GHK-Cu.

Concentration10mg / mL
Volume drawn0.125mL
Doses per vial40doses
Per unit100mcg / unit

Check12.5 units falls between the printed lines on a 1 mL U-100 syringe. Mixing with 4.8 mL of water instead would put this dose at 12 units.

Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects

  • Injection site stinging, redness or irritationCommunity practice

    Commonly reported

    Reported more often than with most peptides in this category.

  • Temporary blue discolouration at the injection siteCommunity practice

    Occasionally reported

    The compound is blue; this is cosmetic, not a sign of harm.

  • Nausea or headacheCommunity practice

    Occasionally reported

  • Effects of sustained copper loadingCommunity practice

    Unknown

    Injecting a copper complex daily delivers copper. Whether that matters at these doses has not been studied.

When to stop

  • Signs of infection at an injection site: spreading redness, warmth, swelling, pus, or fever.
  • Any allergic response: rash, hives, facial swelling, or difficulty breathing. Seek urgent care.
  • Persistent nausea, abdominal pain or fatigue, which are among the features of copper excess.
  • Injection site reactions that intensify with each dose.

Interactions and situations that need care

  • Wilson's disease or any copper metabolism disorderAvoid

    Wilson's disease is a genetic inability to clear copper properly. Deliberately injecting a copper-carrying compound is directly contrary to its management.

  • Copper supplementationUse caution

    GHK-Cu delivers copper. Taking it alongside a copper supplement stacks the same input from two directions without either source accounting for the other.

  • Pregnancy and breastfeedingAvoid

    No reproductive or developmental safety data for injected use.

  • Active or previous cancerUse caution

    Copper is involved in angiogenesis, and copper-lowering has itself been investigated as an anti-cancer strategy. No study has examined injected GHK-Cu in people with cancer.

What to expect

HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.

  • Human evidence for GHK-Cu is topical. If you are injecting it, the studies most often cited in support are not studies of what you are doing.
  • Skin changes reported in topical studies developed over weeks to months of consistent application.
  • The blue colour of the solution and any temporary tint at the injection site are expected properties of a copper complex, not signs of anything going wrong.

Storage and handling

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. The solution is characteristically blue; that colour is expected and is not a fault.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Printable one-pagerHow to reconstitute a vial, step by step

With other peptides

  • AHK-Cucaution

    Both deliver copper into tissue, and using them together means doing that by two routes at once. This is the copper peptide with the actual dermatological research behind it.

Check this against a whole stack

In use

Stacks with GHK-Cu in them

Documented combinations, with full schedules.

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.

  • Blue powder, blue solution

    The copper complex is blue. A GHK-Cu vial that is not blue once mixed is not GHK-Cu.

  • Colourless after mixing

    Suggests the material is not the copper complex it was sold as.

  • Cloudy or particulate

    Indicates degraded or contaminated material.

Questions

Why is my GHK-Cu solution blue?
Because it is a copper complex, and copper complexes of this kind are blue. A vial that mixes to a colourless solution is unlikely to be what it was sold as.
Is the topical research relevant to injecting it?
Not directly. The large majority of GHK-Cu research concerns topical application to skin or laboratory work on cultured cells. Injected use at community doses has not been studied, and it is a different exposure entirely.
How much GHK-Cu is in a GLOW blend?
In a typical 70 mg GLOW vial, 50 mg is GHK-Cu. Five times the amount of either other component. Someone dosing that blend by its BPC-157 content is taking five times as much GHK-Cu as BPC-157 with every draw.

References

  1. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline

    Brain Sciences, 2017 · Review of gene expression and preclinical work

    Cultured human cells and animal models

    Reviews reported effects of GHK on genes involved in tissue remodelling, inflammation and repair, and summarises the topical and in vitro literature.

    10.3390/brainsci7020020

  2. Commonly reported community protocols

    Bioalmanac editorial summary of public community sources, 2026 · Not a study

    Summarises the injected dose ranges most consistently described in public discussion. Carries no evidential weight about safety or effect.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.

Page last updated 12 Aug 2026